Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure
- Author:
Jae Yong YOON
1
;
Dong Heon YANG
;
Hyun Jun CHO
;
Nam Kyun KIM
;
Chang Yeon KIM
;
Jihyun SON
;
Jae Hyung ROH
;
Se Yong JANG
;
Myung Hwan BAE
;
Jang Hoon LEE
;
Hun Sik PARK
;
Yongkeun CHO
;
Shung Chull CHAE
Author Information
- Publication Type:Original Article
- From:The Korean Journal of Internal Medicine 2019;34(4):811-818
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS:Carbohydrate antigen 125 (CA-125) is an emerging prognostic biomarker for heart failure. We aimed to test the long-term prognostic value of CA-125 in combination with N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute decompensated heart failure (ADHF).
METHODS:This observational study included a total of 413 patients (64.1 ± 15.6 year-old, 214 men) with ADHF. All-cause mortality during the 2-year follow-up was investigated for the prognosis.
RESULTS:During the follow-up (mean follow-up, 591 ± 233 days), 109 deaths (26.0%) were recorded. In the multivariable analysis model, CA-125 was an independent factor associated with all-cause mortality (log CA-125: hazard ratio, 1.23; 95% confidence interval, 1.02 to 1.48; p = 0.030) together with age, sex, New York Heart Association class, β-blocker, and NT-proBNP. The Kaplan-Meier survival analysis demonstrated that the group with both low marker levels showed the best 2-year survival (87.9%) followed by the group with low NT-proBNP and high CA-125 (76.1%), high NT-proBNP and low CA-125 (64.7%) and high NT-proBNP and high CA-125 levels (54.3%) (p < 0.001). Addition of CA-125 in combination with NT-proBNP and established risk factors further increased the predictive power for mortality in patients with ADHF.
CONCLUSIONS:CA-125 was an independent factor associated with all-cause mortality in patients with ADHF. Combination of CA-125 with NT-proBNP significantly improved the prediction of mortality in patients with ADHF.
